Division of Pharmacotherapeutics, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan; Department of Pharmacy, Showa University Fujigaoka Hospital, Kanagawa, Japan.
Division of Pharmacotherapeutics, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan.
Clin Ther. 2024 Jan;46(1):12-19. doi: 10.1016/j.clinthera.2023.10.006. Epub 2023 Nov 7.
In Japan, carperitide has been recommended for the treatment of pulmonary congestion in patients with acute heart failure. Identifying useful indicators to support the decision to administer carperitide and the optimal timing of administration may lead to better improvement of pulmonary congestion. Therefore, we investigated the factors associated with good diuretic response to carperitide in patients with acute heart failure and the optimal timing of carperitide administration.
This retrospective cohort study investigated 293 hospitalized patients who were diagnosed with acute heart failure and treated with carperitide at the Department of Cardiology, Showa University Fujigaoka Hospital. The primary endpoint was the diuretic response to carperitide. Patients with urine output ≥100 mL/h were defined as the good diuretic response group, and those with a urine output <100 mL/h during the first 6 hours of carperitide administration were defined as the poor diuretic response group. Multivariate analysis was used to examine the predictors of good diuretic response. The relationship between the time from intravenous furosemide to carperitide administration and urine output was also investigated.
The patients' median age was 77 (range: 28-99) years, and 75.5% had New York Heart Association stage IV acute heart failure. The median urine output within 6 hours of carperitide administration was 104.5 (range: 6.6-1571.3) mL/h, and 118 patients (53.6%) showed a good diuretic response. Significant predictors of good diuretic response were age < 75 years [odds ratio (OR) 4.186; 95% confidence interval (CI), 2.129-8.230; P < 0.001], no prior use of loop diuretics (OR 2.155; 95% CI, 1.104-4.207; P = 0.024), blood urea nitrogen <20 mg/dL (OR 2.637; 95% CI, 1.340-5.190; P = 0.005), and white blood cell count <8.6 × 10/L (OR 3.162; 95% CI, 1.628-6.140; P = 0.001). The median urine output in the group with <2 hours between intravenous furosemide and carperitide administration was significantly higher than that in the group with an interval >6 hours [127.3; interquartile range (IQR), 77.6-216.2 mL/h vs. 66.2; IQR. 51.8-114.8 mL/h; P = 0.012).
The 4 predictors (age, no prior use of loop diuretics, blood urea nitrogen, and white blood cell count) of good diuretic response are useful indicators to support decision-making for carperitide administration. Additionally, the administration of carperitide within 2 hours of intravenous furosemide may lead to the improvement of pulmonary congestion.
在日本,卡贝缩宫素已被推荐用于治疗急性心力衰竭患者的肺充血。确定支持给予卡贝缩宫素的有用指标和最佳给药时间,可能会改善肺充血的改善情况。因此,我们研究了与急性心力衰竭患者使用卡贝缩宫素的利尿反应良好相关的因素,以及卡贝缩宫素的最佳给药时间。
这项回顾性队列研究调查了在昭和大学藤冈医院心内科住院的 293 名诊断为急性心力衰竭并接受卡贝缩宫素治疗的患者。主要终点是卡贝缩宫素的利尿反应。尿输出量≥100 mL/h 的患者定义为利尿反应良好组,卡贝缩宫素治疗的前 6 小时内尿输出量<100 mL/h 的患者定义为利尿反应不良组。使用多变量分析来检查利尿反应良好的预测因素。还研究了静脉注射呋塞米与卡贝缩宫素给药之间的时间与尿输出量之间的关系。
患者的中位年龄为 77 岁(范围:28-99 岁),75.5%为纽约心脏协会(NYHA)Ⅳ级急性心力衰竭。卡贝缩宫素给药后 6 小时内的中位尿量为 104.5(范围:6.6-1571.3)mL/h,118 名患者(53.6%)表现出良好的利尿反应。良好利尿反应的显著预测因素是年龄<75 岁(比值比[OR] 4.186;95%置信区间[CI],2.129-8.230;P<0.001)、无环利尿剂(OR 2.155;95%CI,1.104-4.207;P=0.024)、血尿素氮<20 mg/dL(OR 2.637;95%CI,1.340-5.190;P=0.005)和白细胞计数<8.6×10/L(OR 3.162;95%CI,1.628-6.140;P=0.001)。静脉注射呋塞米后<2 小时给予卡贝缩宫素的组中位尿量明显高于间隔>6 小时的组[127.3;四分位距(IQR),77.6-216.2 mL/h vs. 66.2;IQR,51.8-114.8 mL/h;P=0.012]。
4 个预测因素(年龄、无环利尿剂的使用史、血尿素氮和白细胞计数)是支持卡贝缩宫素给药决策的有用指标。此外,在静脉注射呋塞米后 2 小时内给予卡贝缩宫素可能会改善肺充血。